Albany, NY -- (SBWire) -- 03/22/2016 --Transparency Market Research has compiled numerous market intelligence reports on the global biotechnology industry. One such report is titled "EpCAM Antagonists Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023." It provides a holistic study of the global EpCAM antagonists market, describing all the possible drivers, restraints, opportunities of growth, and trends in the market in the recent past and the near future.
EpCAM is short for epithelial cell adhesion molecule. It is one of the most expressed antigens present in some of the most common cancer types, including lung cancer, gastric cancer, breast cancer, prostate cancer, colon cancer, and ovarian cancer. Extensive research has shown that EpCAM is a strong market for cancer that originates from epithelial sources. It is also considered as a primary target for cancer-related therapy.
EpCAM is one of the major proteins responsible for the differentiation, migration, signaling, proliferation, and adhesion of epithelial cells. One of the major characteristics of EpCAM is that it is not present in cancer that does not stem from epithelial sources or even other non-epithelial cells. It is mostly expressed in stem cells, progenitor cells, and epithelial tissues.
The global EpCAM antagonists market is currently propelled by the growing incidence of multiple cancer types across the world. This has caused a high rate of research and development efforts to be established in this market. Another factor promoting the growth of the global EpCAM antagonists market is the consistent development in the field of recombinant DNA technology. Advancements in this field could help produce EpCAM antagonists with high efficacy. The global EpCAM antagonists market is further propelled by the growing number of supportive funding schemes provided by various governments.
Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4678
The global EpCAM antagonists market thus plays a vital role in the cancer treatment industry. Two of the most commonly used EpCAM antagonists are Edrecolomab and Catumaxomab. The former is generated from mouse-based antibodies and is sold by Johnson & Johnson under the brand name Panorex. Edrecolomab is used for the treatment of colorectal cancer. Catumaxomab can bind with EpCAM and CD3 and is used in the treatment of malignant ascites in patients suffering from metastasizing tumors. It is currently developed by Trion Pharma and Fresenius Biotech. It is also a rat-based antibody and is commercially sold as Removab.
The key players in the global EpCAM antagonists market are the American Association for Cancer Research, the University of Hong Kong, Trion Pharma GmbH, Johnson & Johnson, Fresenius Biotech, and Amgen, Inc. The competitive landscape comprises research institutes, academies, and some of the top medical companies in the world.
Contact us:
Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/
Global EpCAM Antagonists Market Boosted by Consistent Research and Development Efforts
Transparency Market Research Report Added "EpCAM Antagonists Market" to its database.